• The Journal of Pediatrics of Korean Medicine
• /
• v.26 no.3
• /
• pp.20-29
• /
• 2012

Objectives The purpose of this case study is to report the effect of concurrent administration of Danguieumja-gagambang and external treatments on childhood psoriasis. Methods The subject is a child with psoriasis. This patient was treated with oriental herbal medicine (Danguieumjagagambang) and external treatments. The improvement of the skin condition is observed by Psoriasis Area and Severity Index (PASI) score. Results After the treatment, the symptoms of psoriasis were relieved. PASI score of this child went down from 4.7 to 0. Conclusions This study showed that concurrent administration of Danguieumja-gagambang and external treatments can be an effective choice for psoriasis.

• The Journal of Pediatrics of Korean Medicine
• /
• v.19 no.2
• /
• pp.13-30
• /
• 2005

Objective: Danguieumja-gagambang (DGEJGB), a traditional Korean prescription, has been used as therapeutics for allergic diseases such as atopic dermatitis (AD). In this study, we compared with regulatory Effect of Atopic Allergic Reaction by Prescriptions A and by Prescriptions B. Methods : To evaluate and compare the atopic allergic effectiveness of two prescription (A, B) of DGEJGB, the author investigated a possible effect of DGEJGB on mast cell-mediated allergic reaction, cytokine secretion and mRNA expression in vivo and in vitro. Results : Mast cells are a potent source of mediators that regulate the inflammatory response in allergic reaction. In mice orally administered A, B of DGEJGB ( 0.1, 0.1 and 1.0 g/kg) for 1 h, compound 48/80-induced ear swelling was significantly reduced. Significant reduced levels (P < 0.05). of tumor necrosis factor $(TNF)-{\alpha}$ was observed in the human mast cell line (HMC-1) with DGEJGB (A). IL-6 and IL-8 secretion were significantly inhibited by DGEJGB (A, B). In addition, $TNF-{\alpha}$ and IL-8 mRNA expression were reduced by DGEJGB (A) at the dose of 0.01 mg/ml without cell toxicity. Conclusions : These results suggest that DGEJGB (A) contributes to the treatment of atopic allergic reactions rather than DGEJGB (B), and that its action may be due to inhibition of cytokine secretion and mRNA expression HMC-1.